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subjects attending all assessment visits. There was one treat-
ment protocol termination; this subject discontinued HLXL Dan
after week 1 because of a rise in serum transaminase levels.
According to pill counts, overall compliance with study drug was
94 percent. There were no serious adverse events reported.
Overall, there was a signiﬁcant reduction in VAS knee pain that
was evident by week 3 and continued through the end of the
study (see Tables). While there was no signiﬁcant change in the
patient global assessment of disease during the intervention (P
= 0.37), 3 patients reported that they were markedly improved, 2
were moderately improved, and 1 each was slightly improved or
had no change at the ﬁnal visit.
Mean (SE) VAS Knee Pain
Baseline Week 1 Week 3 Week 6 Model F (df) P value
53.5 (5.2) 49.6 (5.2) 42.5 (5.4) 34.3 (5.4) 8.08 (16) 0.002
Mean (SE) Change in VAS Knee Pain
Period Mean (SE) P value
BL to WK 1 -3.9 (3.9) 0.34
BL to WK 3 -11.0 (4.2) 0.02
BL to WK 6 -19.2 (4.2) 0.0003
Conclusions: HLXL Dan at a single daily dose of 5,180 mgs
for six weeks was safe and efﬁcacious in this phase I study in
patients with symptomatic knee OA. A Phase II dose-ranging
placebo-controlled clinical trial of this herbal compound, sup-
ported by a grant from NCCAM, is currently being conducted.
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Purpose: Primary ﬁnding in knee osteoarthritis (OA) is gait
abnormalities. Also, decrease in muscle strength and range
of motion reduced functional capacity, impaired balance and
proprioception together with resultant increased risk of falling
have been reported. The purpose of this study was to investigate
the effects of two physical therapy and rehabilitation programs on
functional capacity, proprioception, and balance in women with
knee OA.
Methods: Forty female patients with knee OA participated in
this study. Patients were randomly and equally divided into two
groups. Group I underwent a physical therapy and rehabilitation
program consisting of hotpack, ultrasound, and proprioceptive
neuromuscular facilitation (PNF) exercises for a total 10 sessions,
5 days per week for 2 weeks. They continued PNF exercises for
3 days per week for additional 4 weeks. Group II underwent
hotpack, ultrasound, and isokinetic exercises for 5 days per
week, for 2 weeks (a total of 10 sessions). Similar to Group
I, they continued isokinetics exercises for 3 days per week for
additional 4 weeks. Patients were evaluated at baseline at the
second and the sixth weeks of treatment. Functional capacity
was evaluated using 15- meter walking distance, time up and go
test and 12- step up and down test. Proprioception was evaluated
using isokinetic dynamometer, and static and dynamic balance
was evaluated using kinesthetic ability trainer.
Results: Functional capacity, proprioception, and balance im-
proved signiﬁcantly in both groups (p<0.05). There were no
signiﬁcant differences between the groups in any of the variables
both at the second and the sixth week of treatment in any of the
groups (p>0.05).
Conclusions: Two different physical therapy and rehabilitation
programs had favorable effects on functional capacity, proprio-
ception and balance in women with knee OA. Therefore, both
programs can be used to improve these parameters in patients
with knee OA.
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Purpose: To compare the pharmacokinetics of glucosamine
following treatment with glucosamine sulphate or glucosamine
hydrochloride in a large animal model and to compare the syn-
ovial ﬂuid levels attained following the administration of each
formulation at clinically relevant doses.
Methods: Eight adult female horses were used. After an
overnight fast, crystalline glucosamine sulphate (Dona®) or glu-
cosamine hydrochloride were administered at a dose of 20 mg/kg
by either intravenous (IV) injection or nasogastric (NG) intuba-
tion. Plasma samples were collected before dosing and at 5,
15, 30, 60, 120, 360, 480 and 720 minutes after dosing. Syn-
ovial ﬂuid samples were collected from the radio-carpal joints
within 48 hours before dosing and at 1, 6 and 12 hours post
dosing. Glucosamine was measured in both plasma and syn-
ovial ﬂuid by Liquid Chromatography Electrospray Tandem Mass
Spectrometry (LC-ESI/MS/MS).
Results: Endogenous plasma and synovial glucosamine con-
centrations were not signiﬁcantly different and ranged between
< 10 ng/mL (LOQ) and 39.1 ng/mL. Following IV injection of
either compound, plasma concentrations reached ∼ 50 µg/mL
and declined in a similar multi-exponential fashion. After NG ad-
ministration, plasma concentrations attained ∼ 1 µg/mL for both
types of glucosamine with no signiﬁcant difference in attained
median maximal plasma concentrations. The median elimination
half-life of glucosamine after oral glucosamine sulphate admin-
istration was 4.0 hours and 3.0 hours after oral glucosamine
hydrochloride administration. The median oral bioavailability was
marginally but not signiﬁcantly higher for glucosamine sulphate
than for glucosamine hydrochloride and reached 9.4 % and 6.1 %
respectively. The AUC0-12hr and the AUC0-inf were signiﬁcantly
higher and the relative clearance was signiﬁcantly lower after
oral glucosamine sulphate treatment compared to glucosamine
hydrochloride treatment. The median maximal synovial ﬂuid con-
centrations were signiﬁcantly higher following oral treatment with
glucosamine sulphate (158.3 ng/mL) compared to oral adminis-
tration of glucosamine hydrochloride (88.9 ng/mL). The difference
in synovial ﬂuid concentrations attained following NG adminis-
tration was statistically signiﬁcant at 1 and 6 hours, but not at
12 hours post treatment. Twelve hours after oral treatment with
glucosamine hydrochloride, plasma and synovial glucosamine
levels had returned to baseline levels. Following oral adminis-
tration of glucosamine sulphate, glucosamine levels in plasma
and the synovial ﬂuid were still signiﬁcantly higher than base-
line twelve hours post-treatment. The difference in synovial ﬂuid
glucosamine concentrations attained between treatment groups
was not statistically signiﬁcant following IV treatment.
Conclusions: Following oral administration of a clinically rec-
ommended dose of glucosamine sulphate (Dona®), signiﬁcantly
higher synovial ﬂuid concentrations of glucosamine are attained,
